<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple primary lung cancers</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple primary lung cancers</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple primary lung cancers</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas E Stinchcombe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shamus R Carr, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Vallières, MD, FRCSC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4882313"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with lung cancer may present with two primaries at the same time (synchronous multiple primary lung cancer) or may develop a second, metachronous primary lung cancer after treatment of the initial lesion. This is becoming a more common clinical issue and remains a challenge due to how these tumors are classified [<a href="#rid1">1</a>].</p><p>Multiple primary lung cancers (MPLC) pose a variety of clinically important diagnostic and therapeutic problems, which may differ from those in patients presenting with a single primary tumor. These issues are reviewed here for both synchronous and metachronous MPLC.</p><p class="headingAnchor" id="H25476385"><span class="h1">DIAGNOSTIC CRITERIA</span></p><p class="headingAnchor" id="H25476393"><span class="h2">Synchronous MPLC</span><span class="headingEndMark"> — </span>Patients presenting with more than one pulmonary nodule at the same time must fulfill strict criteria to be classified as having synchronous MPLC [<a href="#rid2">2,3</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Both lesions must be malignant and must arise independently in the lung. The second lesion cannot be assumed to represent a second primary lung cancer. A benign nodule, infectious process, or metastasis from an extrapulmonary site must be excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second malignant lesion must not represent a metastasis from the first lung lesion. Accepted criteria for this distinction include [<a href="#rid4">4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Different histology or origin from a separate focus of carcinoma in situ.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Same histology, but anatomically distinct, without involvement of the mediastinum (N2, N3 negative), and without systemic metastases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Same histology, but clearly different based upon a comprehensive histologic assessment:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Determination of the predominant subtype</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Relative percentage of each histologic subtype estimated in 10 percent increments</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cytological features to include: grade, necrosis, inflammation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Different pattern of biomarkers utilizing gene sequencing technologies.</p><p></p><p class="headingAnchor" id="H25476778"><span class="h2">Metachronous MPLC</span><span class="headingEndMark"> — </span>Patients with a history of a previously treated lung cancer are at increased risk for the development of a second lung cancer. The diagnostic issues in these patients and their subsequent management pose different issues than for synchronous MPLC.</p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis includes a benign nodule, infectious process, or a metastasis from extrapulmonary primary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The tumors are considered metachronous if the histology is different or if they are the same histology and there is a four year or greater interval between the cancers with no evidence of systemic metastases [<a href="#rid5">5</a>]. With a shorter interval between two primary tumors, the prognosis might be less favorable but the treatment options would generally be similar in the absence of other systemic metastatic disease.</p><p></p><p class="headingAnchor" id="H25476813"><span class="h2">TNM staging system implications</span><span class="headingEndMark"> — </span>The definitions in the eighth edition of the American Joint Committee on Cancer (AJCC) Tumor, Node, Metastasis (TNM) staging system have important implications for classifying a patient as having MPLC  (<a class="graphic graphic_table graphicRef109805" href="/z/d/graphic/109805.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Histologically identical lesions within the same lobe are considered to be "separate tumor nodules" and are classified as being a single T3 tumor, and this is not considered a MPLC [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A secondary lesion with identical histology located in a different lobe of the ipsilateral lung is considered a T4 lesion. Thus, some cases that were previously considered as stage IV disease or MPLC in the sixth edition of the staging system are classified as T4 tumors.</p><p></p><p>Where clinical guidance is provided in this topic, the eighth edition staging system is used; however, it is recognized that the studies cited may have used previous editions of the staging system, which is a limitation of existing data.</p><p class="headingAnchor" id="H25476413"><span class="h2">Histology</span><span class="headingEndMark"> — </span>There have been substantial changes in the prevalence of various histologies of lung cancer over the last several decades in the United States, with an increasing incidence and proportion of adenocarcinoma and a decreasing frequency of squamous cell carcinoma [<a href="#rid7">7</a>]. In an analysis of cooperative group trials in patients with non-small cell lung cancer (NSCLC), the majority of patients had adenocarcinoma (58 percent), followed by squamous (20 percent) and large cell carcinoma (8 percent) [<a href="#rid8">8</a>]. The rate of small cell lung cancer (SCLC) is decreasing as well [<a href="#rid9">9</a>]. Thus, in the United States the most likely clinical scenario is a patient with two lesions, both of which are adenocarcinoma. This is why simple demonstration of the same histologic type is not sufficient to classify the lesions as metastasis. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a>.)</p><p>Advanced molecular testing such as DNA fingerprinting may be able to determine if the two lesions are separate primaries or the same lung cancer, but these are not available for routine clinical use and are only suggestive, but not definitive, in establishing relatedness. Comprehensive molecular testing has become the standard of care for patients with advanced NSCLC, and testing for programmed cell death ligand 1 and epidermal growth factor receptor (<em>EGFR</em>) mutations is standard for patients with resected NSCLC [<a href="#rid10">10</a>]. </p><p>Some have suggested use of next-generation sequencing (NGS) panels to help distinguish MPLC from pulmonary metastasis, and to determine if the two lesions have different oncogenic drivers that would suggest two separate primaries. Comprehensive genomic profiling is used to investigate if a patient has metachronous or synchronous multiple primaries [<a href="#rid11">11-13</a>]. Several case series have investigated the role of NGS in distinguishing independent primary tumors from intrapulmonary metastases, and most of these have been from single centers, retrospective, and have included fewer than 50 patients [<a href="#rid14">14-19</a>]. These series suggest a role for NGS when histologic examination is uncertain and cannot determine if the two lesions are separate primaries. While the utility of this approach is greater when one of the tumors has a classic oncogenic-driver molecular alteration, it is potentially a more accurate diagnostic method that does correlate with prognosis [<a href="#rid19">19</a>].</p><p>A special clinical entity previously known as bronchioloalveolar carcinoma is now recognized as a spectrum ranging from adenocarcinoma in situ, to minimally invasive adenocarcinoma, to invasive adenocarcinoma with a range of growth patterns from lepidic predominant to mucinous [<a href="#rid20">20</a>] and represents an increasing proportion of lung adenocarcinoma in some but not all series [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Adenocarcinoma'</a>.) </p><p>This spectrum can frequently present as multifocal tumors (often referred to as multifocal adenocarcinoma) generally representing separate primary tumors rather than metastatic disease given their tendency to local rather than distant progression [<a href="#rid21">21</a>]. Multifocal disease has a characteristic appearance on computed tomography (CT), with lesions in varying states of progression from pure ground glass to partially solid to solid nodules, with individual tumors progressing over time at varying rates from very indolent over years to aggressive over months. As it may not be feasible to resect all the lesions, management of this scenario requires special consideration. (See <a class="local">'Management'</a> below.) </p><p class="headingAnchor" id="H25476539"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Lung cancer has been causally linked to tobacco smoke in most cases, as well as to a wide range of other environmental risk factors. In addition, there is some evidence of a genetic contribution to the development of lung cancer for both smoking and nonsmoking-related lung cancer, especially in adenocarcinoma [<a href="#rid23">23,24</a>]. Tobacco and other carcinogens create a "field effect" in which multicentric cancers can arise in a benign contiguous tissue [<a href="#rid25">25</a>]. Importantly, the history of tobacco use predisposes patients to a variety of second cancers, and depending on the clinical presentation, a work-up for extrapulmonary second primary should be considered [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.)</p><p>A literature review estimated that patients who underwent complete resection of a non-small cell lung cancer (NSCLC) have a risk of 1 to 2 percent per patient-year for the development of a second lung cancer [<a href="#rid27">27-29</a>]. Likewise, patients with small cell lung cancer (SCLC), who had been successfully treated, developed a second primary lung cancer at a rate of 6 percent per patient-year. In another study of patients with SCLC, the overall risk of a second cancer was 3.5 times higher compared with the general population [<a href="#rid30">30</a>].</p><p>Patients who continue to smoke have an increased risk of developing a second lung cancer compared with those who do not use tobacco [<a href="#rid27">27,29-32</a>]. The risk of a second primary lung cancer and its relationship to smoking were prospectively illustrated in a phase III chemoprevention trial, in which patients with resected stage I NSCLC were randomly assigned to <a class="drug drug_general" data-topicid="9884" href="/z/d/drug information/9884.html" rel="external">selenium</a> or placebo [<a href="#rid33">33</a>]. The rate of second primary lung cancers in the selenium and placebo arms was 1.62 and 1.30 per 100 person-years (p = 0.29). The overall survival was significantly different by smoking status. The rate of a second primary lung cancer or a recurrence among patients who were active smokers, former smokers, or never smokers was 30, 24, and 20 percent.</p><p class="headingAnchor" id="H25476771"><span class="h1">SYNCHRONOUS MPLC</span></p><p class="headingAnchor" id="H94494966"><span class="h2">Diagnostic and staging evaluation</span><span class="headingEndMark"> — </span>The diagnosis of synchronous MPLC requires tissue to characterize both lung tumors. This is due to the fact that nodules in the ipsilateral lung are generally regarded as metastases. These are even more complex as multiple adenocarcinomas are reported to account for as much as 50 percent or greater of synchronous MPLC [<a href="#rid34">34,35</a>]. The information from histologic examination can provide the basis for characterizing some patients has having MPLCs. </p><p>The staging of a patient presenting with more than one primary lung cancer is complex and needs to be meticulous if potentially curative resection is being contemplated. Both magnetic resonance imaging (MRI) scan of the brain and a fluorodeoxyglucose positron emission tomography (FDG-PET) should be performed to evaluate for extrathoracic metastases.</p><p>Current guidelines for staging the mediastinum do not recommend invasive confirmation of mediastinal lymph node status for patients with peripheral stage IA non-small cell lung cancer (NSCLC) unless there is increased uptake on FDG-PET or increased size on computed tomography (CT) scan of the mediastinal lymph nodes [<a href="#rid36">36,37</a>]. This is based on the low pre-test probability of occult mediastinal lymph node involvement in this clinical situation. </p><p>However, there are insufficient data to determine the probability of mediastinal involvement in a patient with synchronous MPLC; therefore, invasive mediastinal staging cannot be omitted in patients for whom definitive resection is considered. Furthermore, when pathologic involvement of the mediastinal lymph nodes is present, it is more likely that a synchronous lesion represents an intrapulmonary metastasis than a second primary [<a href="#rid5">5</a>]. Thus, invasive staging of the mediastinum provides additional information about the potential for surgical resection and assists in clarifying whether the patient has two synchronous primaries or intrapulmonary metastases. </p><p>With differing histology in the MPLCs, treatment should be based upon providing the best long-term outcomes, with each tumor evaluated and treated irrespective of the other tumor. However, with similar histology in both tumors, this approach depends upon the certainty that the two lesions are indeed distinct.</p><p>Patients with multiple tumors with the same histology and N2 nodal involvement are generally treated as stage IV disease since a single malignant process is likely, but not definitively, responsible for all the lesions.</p><p class="headingAnchor" id="H94494985"><span class="h2">Management</span></p><p class="headingAnchor" id="H94495180"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Surgery is a standard approach for treatment in patients with either synchronous or metachronous MPLC if there is sufficient pulmonary reserve after resection of more than one lesion. However, limited pulmonary reserve may require a patient to undergo a limited resection (eg, segmentectomy or wedge resection) of one or both lesions, or definitive non-operative local therapy. Hybrid approaches combining both surgical and nonsurgical (eg, stereotactic body radiation therapy [SBRT], ablation) modalities have been utilized. When a hybrid approach is utilized, the location of the tumors and the pulmonary reserves of the patient, as discussed below, are taken into consideration. (See  <a class="medical medical_review" href="/z/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Surgical candidates'</a>.)</p><p>Once the diagnosis of synchronous primary lung cancers has been established, the patient should be assessed for potential surgical resection of both lesions. Patients should undergo complete anatomic resection of both tumors, and a significant percentage of patients who undergo resection of both lesions will have mean long-term survival that exceeds 60 months [<a href="#rid38">38-40</a>].</p><p>There are no randomized trials confirming the efficacy of this approach; most of the data are retrospective, from single centers, and subject to both patient selection and publication bias. Furthermore, these analyses were performed before the widespread adoption of FDG-PET staging. Patients were also very carefully selected to undergo resection of both lesions based on comorbidities, pulmonary function, and anatomic location of the tumors. The location is quite important in light of the current definitions for the staging system. Two separate nodules on the same side with the same histology are now characterized as T4 and no longer considered metastatic disease.</p><p>In some instances, two synchronous tumors may have similar histology, and it may be impossible to determine whether or not these represent two primary tumors. In this situation, it may be appropriate to treat such patients as if these represent two primary lesions since that represents the "best case scenario," rather than to characterize them as having stage IV disease.</p><p class="headingAnchor" id="H94495187"><span class="h3">Non-operative local therapy</span><span class="headingEndMark"> — </span>For patients who are not candidates for surgical resection of one or more lesions after appropriate cardiopulmonary work-up, other therapeutic options may achieve prolonged or definitive control of local disease. The data with these approaches are derived from patients with medically inoperable early-stage NSCLC. </p><p>Potential options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Preferred: Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR). (See  <a class="medical medical_review" href="/z/d/html/4617.html" rel="external">"Stereotactic body radiation therapy for lung tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Conventional radiation therapy. (See  <a class="medical medical_review" href="/z/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Nonsurgical candidates'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous image-guided tumor ablation. (See  <a class="medical medical_review" href="/z/d/html/4624.html" rel="external">"Image-guided ablation of lung tumors"</a>.)</p><p></p><p>The advantages and limitations of each of these approaches for the treatment of lung cancer are discussed separately, as noted above.</p><p>For stage I NSCLC, prospective trials and population-based comparative analyses have found SBRT to be associated with higher local tumor control rates and overall survival compared with conventional radiation therapy or radiofrequency ablation, and similar compared with surgery in matched patient cohorts [<a href="#rid41">41-46</a>].</p><p>In patients with synchronous lesions, non-operative local therapy, especially SBRT, may have a role either to treat both lesions, or, in conjunction with surgery, in situations where the patient is thought to be unable to tolerate the surgery necessary to resect both primary lesions. The available data indicate the safety and potentially curative role of SBRT in MPLC, particularly in patients at high risk of surgical complications.</p><p>Seven retrospective studies of SBRT for MPLC with a total of 304 patients (with 10 to 101 patients in each study) treated with either SBRT to all lesions or a combination of surgery and SBRT for different lesions have been reported [<a href="#rid47">47-53</a>]. The majority of patients were medically inoperable. Median overall survival was 20 to 46 months. Two-year local tumor control rate was 81 to 99 percent. High-grade toxicities were rare. Patients with synchronous MPLC had lower overall and progression-free survival than those with metachronous MPLC. </p><p>For the special case of multifocal synchronous MPLC, especially the spectrum of adenocarcinoma formerly known as bronchioloalveolar carcinoma, resection of all lesions even using parenchyma-sparing techniques may not be feasible. </p><p>The highest-risk lesion(s) based on histologic grade or radiologic features (eg, growth, size and solid component, FDG uptake on PET) should be treated with definitive local therapy if possible, while lesions at low risk of becoming symptomatic (eg, small subsolid nodules with slow growth) may be observed until they demonstrate more aggressive radiologic features [<a href="#rid54">54</a>]. </p><p>Because additional lesions may evolve to more aggressive growth and require treatment, use of parenchyma-sparing approaches is preferred, and stronger consideration of non-operative local therapy is warranted even as the initial approach. Definitive local therapy of additional lesions should be considered at the point they demonstrate potential for symptomatic progression (eg, subsolid nodules with accelerating growth or increasing solid component or increasing FDG uptake, even while small). Multifocal progression not amenable to definitive local therapy may warrant systemic therapy as for metastatic disease.</p><p class="headingAnchor" id="H25476971"><span class="h1">METACHRONOUS MPLC</span><span class="headingEndMark"> — </span>Many patients who are successfully treated for non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) will develop a second primary lung cancer. In appropriately selected patients with metachronous NSCLC, surgical resection of the second primary can provide long-term survival [<a href="#rid55">55</a>]. Based on retrospective studies, the median time interval between the primary and the new lung cancer is 38 to 48 months, and approximately two-thirds of the tumors have the same histology [<a href="#rid5">5,56</a>]. </p><p>One of the biggest challenges in treating a second primary is assessing if surgical resection is feasible. Approximately two-thirds of the metachronous lung cancers are resectable and approximately one-third of the patients who undergo a resection will have a limited resection [<a href="#rid5">5</a>]. However, limited resection (at least an anatomic segmentectomy) should be attempted in all cases. Segmentectomies have been shown to have similar outcomes to lobectomy in terms of recurrence-free survival, especially for tumors under 3 cm in size [<a href="#rid57">57</a>]. Additionally, segmentectomies can be safely performed either open or thoracoscopically and have significantly less impact on pulmonary function. A few small, single-institution studies have demonstrated both feasibility and superiority of repeat surgery compared with a non-operative approach for MPLC [<a href="#rid56">56,58</a>]. While there may be an elevated risk of morbidity and mortality within 90 days of surgery, the long-term outcomes are acceptable and superior when compared with similar study outcomes of non-operative intervention case series. The key point is that the patient must be able to tolerate the additional resection.</p><p>Patients with metachronous MPLC may also benefit from use of nonsurgical approaches, particularly with the reduced pulmonary reserve associated with an earlier resection when they are not candidates for further resection. (See <a class="local">'Non-operative local therapy'</a> above.)</p><p class="headingAnchor" id="H25477186"><span class="h1">ADJUVANT THERAPY FOR RESECTED NSCLC</span><span class="headingEndMark"> — </span>There are no randomized trials to guide the use of adjuvant therapy in patients with MPLC. Therapies should be considered on a case-by-case basis with shared decision-making with the patient.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemotherapy</strong> – Cisplatin-based adjuvant chemotherapy is the standard of care for patients with a single stage II or stage III non-small cell lung cancer (NSCLC) who have undergone a potentially curative resection. This approach is based upon results of phase III trials that have revealed an improvement in overall survival with chemotherapy compared with observation. The data for patients with stage I NSCLC are not definitive, but patients with no nodal involvement and with tumors greater than 4 cm may benefit. (See  <a class="medical medical_review" href="/z/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Patients treated with initial surgical resection'</a>.)</p><p></p><p>For patients with synchronous MPLC, the highest stage of tumor appears to be the best predictor of prognosis, and if the patient has resected stage II or III disease, then adjuvant chemotherapy is recommended [<a href="#rid59">59</a>]. The uncertain situation is when a patient has two synchronous or metachronous stage I NSCLCs. While patients with stage I NSCLC with MPLC may have a worse prognosis than patients with a single stage I NSCLC, the absolute benefit of adjuvant cisplatin-based chemotherapy is unclear. Clinicians should consider the size of the tumors, the patient's comorbidities, performance status, and preferences in deciding whether or not to use adjuvant chemotherapy in this situation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint inhibitors</strong> – Immune checkpoint inhibitors have changed the management of advanced lung cancer [<a href="#rid60">60</a>]. These drugs are now being reported in small case series and reports for second primary lung cancers and MPLC [<a href="#rid61">61-63</a>]. However, multi-omic analysis can reveal genomic heterogeneity between tumors that may result in a distinctly different response to immunotherapy. </p><p></p><p>A phase III trial of adjuvant <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> compared with standard of care in patients with resected NSCLC who received adjuvant chemotherapy revealed an improvement in disease-free survival (DFS) [<a href="#rid64">64</a>]. This therapy is available for patients with stage II or IIIA disease with a programmed cell death ligand 1 expression of ≥1 percent. Adjuvant <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> has shown promising preliminary results [<a href="#rid65">65</a>], but does not have regulatory approval. The clinical benefit in patients with synchronous primary lung cancers who underwent resection is unknown at this time since only patients with a single primary NSCLC have been enrolled. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>EGFR</strong><strong><em> </em></strong><strong>inhibitors in </strong><strong><em>EGFR</em></strong><strong>-mutant disease</strong> – A phase 3 trial of adjuvant <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> compared with standard of care in patients with stage IB to IIIA resected NSCLC with an epidermal growth factor receptor (<em>EGFR</em>)<em> </em>mutation revealed an improvement in DFS [<a href="#rid66">66</a>]. Similar to the adjuvant immunotherapy trials, the benefit in patients with synchronous primary lung cancers is not known at this time. </p><p></p><p class="headingAnchor" id="H2071452572"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Stage is still considered the most significant predictor of overall survival (OS) after surgical resection of MPLC. However, tumor size &gt;2 cm and number of pack-years of smoking are associated with a statistically significant worse outcome. In a retrospective review of 285 patients with synchronous MPLC treated with surgical resection, the five-year disease-free and overall survival observed were 58.7 and 77.6 percent, respectively. On multivariate analysis of OS, male sex, symptomatic disease, and lymph node involvement were associated with a worse prognosis [<a href="#rid67">67</a>].</p><p>Metachronous primary lung cancers have a better prognosis than synchronous lung cancers, and the few retrospective studies that address only this cohort of patients revealed a five-year OS rate from time of diagnosis of the second primary, after surgical resection, of between 27 and 51 percent [<a href="#rid68">68</a>]. Another retrospective study of 161 patients revealed a five-year overall survival rate of 61 percent calculated from the time of the second resection [<a href="#rid40">40,69</a>]. </p><p>The difference in prognosis between synchronous and metachronous MPLC has been difficult to determine due to the small sample sizes of many of the studies and variable definitions and follow-up. A meta-analysis of 22 relevant studies including almost 1800 patients investigated the overall survival differences between synchronous and metachronous MPLC [<a href="#rid39">39</a>]. Eleven studies analyzed overall survival for both synchronous and metachronous MPLC starting from the diagnosis of the first metachronous tumor (n = 580), and found patients with synchronous MPLC had a shorter overall survival. Interestingly, analysis of the nine studies that investigated overall survival starting from diagnosis of the second metachronous tumor (n = 1009) did not demonstrate a difference in overall survival. In the meta-analysis overall, neither histology nor position (unilateral versus bilateral) had an impact on survival. However, this study was limited and was not able to comment on impact of initial staging or nodal involvement [<a href="#rid39">39</a>]. Prior single-institution studies demonstrate that involvement of N1 or N2 lymph nodes was associated with increased mortality compared with no nodal disease (N0) [<a href="#rid68">68,70-72</a>].</p><p>A recent retrospective analysis of the Surveillance, Epidemiology, and End Results database from 2004 to 2015 of patients with metachronous non-small cell lung cancer analyzed outcomes. On multivariate analysis, age, time interval between lung cancers, and type of surgery for the first and second lung cancers were prognostic factors. Patients who underwent lobectomy for the first primary and sublobectomy for the second lung cancer had better outcomes, and a disease-free survival of 24 months was associated with a better outcome [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H25477231"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>For patients who undergo a complete resection of a single non-small cell lung cancer, the National Comprehensive Cancer Network (NCCN) guidelines recommend computed tomography (CT) with or without contrast, history, and physical examination every 6 to 12 months for the first two years [<a href="#rid74">74</a>]. After two years, NCCN recommends a history and physical and low-dose non-contrast-enhanced CT scan annually. There are no available guidelines or recommendations due to a lack of data for follow-up of MPLC. However, for metachronous MPLC, existing guidelines for a single non-small cell lung cancer are reasonable. In patients with synchronous MPLC, a slightly more aggressive follow-up is recommended by the authors. Generally, the first year is every four months, followed by every six months for two years, and then annually starting at year 3. Smoking cessation advice, counseling, and pharmacotherapy are recommended for any patient who continues to use tobacco. </p><p>To date, clinical trials have not established a role of any agent in the prevention of lung cancer. (See  <a class="medical medical_review" href="/z/d/html/4604.html" rel="external">"Chemoprevention of lung cancer"</a>.)</p><p class="headingAnchor" id="H1018203283"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H25477278"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple primary lung cancer (MPLC) is a relatively uncommon entity that seems to be increasing. This may be due to contemporary screening strategies and improvement in survival, which then leads to a concomitantly increased opportunity to develop new primary lung cancers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The increasing incidence of adenocarcinoma will lead to the clinical scenario where both lesions will have the same histology. Multifocal adenocarcinoma is a separate clinical entity that requires special consideration. (See  <a class="medical medical_review" href="/z/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer", section on 'Multiple tumor nodules'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment requires careful coordination and assessment in a multidisciplinary team, which includes a careful review of imaging studies, pathology, and assessment for surgical resection by a thoracic surgeon. All patients with MPLC should be approached with a curative intent, as a select group of patients will experience long-term survival. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage is the most significant predictor of overall survival after resection of MPLC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgery currently is the standard option when feasible. Standard principles of surgical resection to include anatomic resection with either lobectomy or segmentectomy are preferred. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In those patients that are high-risk surgical candidates after appropriate cardiopulmonary testing or who are likely to require treatment for additional lesions, one or potentially multiple lesions can be considered for definitive non-operative local therapy, particularly stereotactic body radiation therapy. (See <a class="local">'Non-operative local therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In those patients with resected synchronous primaries, the decision to give adjuvant platinum-based chemotherapy, targeted therapy, or immunotherapy should be based upon the lesion with the highest stage. For patients with either synchronous or metachronous stage II or III non-small cell lung cancer, adjuvant cisplatin-based chemotherapy should be considered based on the survival benefit observed in patients with a single resected lesion. (See <a class="local">'Adjuvant therapy for resected NSCLC'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies have revealed an improvement in disease-free survival with adjuvant <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> in patients with resected stage II or III disease and programmed cell death ligand 1 expression ≥1 percent and adjuvant <a class="drug drug_general" data-topicid="105441" href="/z/d/drug information/105441.html" rel="external">osimertinib</a> for patients with an epidermal growth factor receptor (<em>EGFR</em>) mutation. These therapies should be considered on a case-by-case basis with shared decision-making with the patient.</p><p></p><p class="headingAnchor" id="H2151170847"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Billy W Loo, Jr, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Homer RJ. Pathologists' staging of multiple foci of lung cancer: poor concordance in absence of dramatic histologic or molecular differences. Am J Clin Pathol 2015; 143:701.</a></li><li><a class="nounderline abstract_t">Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e369S.</a></li><li class="breakAll">NCCN Guidelines Version 4.2016 Non-small cell lung cancer. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.accessed4.5.2016 (Accessed on April 05, 2016).</li><li><a class="nounderline abstract_t">Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016; 11:651.</a></li><li><a class="nounderline abstract_t">Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:290S.</a></li><li><a class="nounderline abstract_t">Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 2009; 4:671.</a></li><li><a class="nounderline abstract_t">Nakamura H, Saji H. Worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 2014; 44:1004.</a></li><li><a class="nounderline abstract_t">Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 2006; 106:2208.</a></li><li><a class="nounderline abstract_t">Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed on March 17, 2021).</li><li><a class="nounderline abstract_t">Girard N, Ostrovnaya I, Lau C, et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15:5184.</a></li><li><a class="nounderline abstract_t">Klempner SJ, Ou SH, Costa DB, et al. The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review. Clin Lung Cancer 2015; 16:334.</a></li><li><a class="nounderline abstract_t">Takahashi Y, Shien K, Tomida S, et al. Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Sci 2018; 109:3634.</a></li><li><a class="nounderline abstract_t">Roepman P, Ten Heuvel A, Scheidel KC, et al. Added Value of 50-Gene Panel Sequencing to Distinguish Multiple Primary Lung Cancers from Pulmonary Metastases: A Systematic Investigation. J Mol Diagn 2018; 20:436.</a></li><li><a class="nounderline abstract_t">Murphy SJ, Harris FR, Kosari F, et al. Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. J Thorac Oncol 2019; 14:1567.</a></li><li><a class="nounderline abstract_t">Chang JC, Alex D, Bott M, et al. Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clin Cancer Res 2019; 25:7113.</a></li><li><a class="nounderline abstract_t">Patel SB, Kadi W, Walts AE, et al. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases. J Mol Diagn 2017; 19:870.</a></li><li><a class="nounderline abstract_t">Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. J Thorac Oncol 2019; 14:844.</a></li><li><a class="nounderline abstract_t">Goodwin D, Rathi V, Conron M, Wright GM. Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing. J Thorac Oncol 2021; 16:1166.</a></li><li><a class="nounderline abstract_t">Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011; 8:381.</a></li><li><a class="nounderline abstract_t">Barsky SH, Cameron R, Osann KE, et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994; 73:1163.</a></li><li><a class="nounderline abstract_t">Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137.</a></li><li><a class="nounderline abstract_t">Carr SR, Akerley W, Hashibe M, Cannon-Albright LA. Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax 2015; 70:1033.</a></li><li><a class="nounderline abstract_t">Carr SR, Akerley W, Cannon-Albright LA. Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol 2018; 13:938.</a></li><li><a class="nounderline abstract_t">Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963.</a></li><li><a class="nounderline abstract_t">Sánchez de Cos Escuín J, Rodríguez López DP, Utrabo Delgado I, et al. Disease Recurrence and Second Tumors in Long-term Survivors of Lung Cancer. Arch Bronconeumol 2016; 52:183.</a></li><li><a class="nounderline abstract_t">Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998; 90:1335.</a></li><li><a class="nounderline abstract_t">Lou F, Huang J, Sima CS, et al. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg 2013; 145:75.</a></li><li><a class="nounderline abstract_t">Aredo JV, Luo SJ, Gardner RM, et al. Tobacco Smoking and Risk of Second Primary Lung Cancer. J Thorac Oncol 2021; 16:968.</a></li><li><a class="nounderline abstract_t">Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997; 89:1782.</a></li><li><a class="nounderline abstract_t">Karp DD, Lee SJ, Shaw Wright GL, et al. A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer. J Clin Oncol 2010; 28S: ASCO #CRA7004.</a></li><li><a class="nounderline abstract_t">Dijkman BG, Schuurbiers OC, Vriens D, et al. The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging 2010; 37:2037.</a></li><li><a class="nounderline abstract_t">Karp DD, Lee SJ, Keller SM, et al. Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 2013; 31:4179.</a></li><li><a class="nounderline abstract_t">Rostad H, Strand TE, Naalsund A, Norstein J. Resected synchronous primary malignant lung tumors: a population-based study. Ann Thorac Surg 2008; 85:204.</a></li><li><a class="nounderline abstract_t">Yu YC, Hsu PK, Yeh YC, et al. Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers? Ann Thorac Surg 2013; 96:1966.</a></li><li><a class="nounderline abstract_t">Detterbeck FC, Jantz MA, Wallace M, et al. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:202S.</a></li><li><a class="nounderline abstract_t">De Leyn P, Lardinois D, Van Schil P, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol 2007; 2:357.</a></li><li><a class="nounderline abstract_t">Finley DJ, Yoshizawa A, Travis W, et al. Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol 2010; 5:197.</a></li><li><a class="nounderline abstract_t">Jiang L, He J, Shi X, et al. Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis. Lung Cancer 2015; 87:303.</a></li><li><a class="nounderline abstract_t">Stella F, Luciano G, Dell'Amore A, et al. Pulmonary Metastases from NSCLC and MPLC (Multiple Primary Lung Cancers): Management and Outcome in a Single Centre Experience. Heart Lung Circ 2016; 25:191.</a></li><li><a class="nounderline abstract_t">Haasbeek CJ, Palma D, Visser O, et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23:2743.</a></li><li><a class="nounderline abstract_t">Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012; 84:1060.</a></li><li><a class="nounderline abstract_t">Dupuy DE. Treatment of medically inoperable non-small-cell lung cancer with stereotactic body radiation therapy versus image-guided tumor ablation: can interventional radiology compete? J Vasc Interv Radiol 2013; 24:1139.</a></li><li><a class="nounderline abstract_t">Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 2014; 149:1244.</a></li><li><a class="nounderline abstract_t">Nagata Y, Hiraoka M, Shibata T, et al. Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015; 93:989.</a></li><li><a class="nounderline abstract_t">Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16:630.</a></li><li><a class="nounderline abstract_t">Sinha B, McGarry RC. Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. Int J Radiat Oncol Biol Phys 2006; 66:1120.</a></li><li><a class="nounderline abstract_t">Matthiesen C, Thompson JS, De La Fuente Herman T, et al. Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer. J Med Imaging Radiat Oncol 2012; 56:561.</a></li><li><a class="nounderline abstract_t">Creach KM, El Naqa I, Bradley JD, et al. Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy. Radiother Oncol 2012; 104:23.</a></li><li><a class="nounderline abstract_t">Griffioen GH, Lagerwaard FJ, Haasbeek CJ, et al. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol 2013; 107:403.</a></li><li><a class="nounderline abstract_t">Chang JY, Liu YH, Zhu Z, et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer 2013; 119:3402.</a></li><li><a class="nounderline abstract_t">Shintani T, Masago K, Takayama K, et al. Stereotactic Body Radiotherapy for Synchronous Primary Lung Cancer: Clinical Outcome of 18 Cases. Clin Lung Cancer 2015; 16:e91.</a></li><li><a class="nounderline abstract_t">Owen D, Olivier KR, Mayo CS, et al. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules. Radiat Oncol 2015; 10:43.</a></li><li class="breakAll">NCCN Guidlines Version 1.2014 Non-Small Cell Lung Cancer http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (Accessed on October 22, 2013).</li><li><a class="nounderline abstract_t">Hamaji M, Ali SO, Burt BM. A meta-analysis of resected metachronous second non-small cell lung cancer. Ann Thorac Surg 2015; 99:1470.</a></li><li><a class="nounderline abstract_t">Fourdrain A, Bagan P, Georges O, et al. Outcomes after Contralateral Anatomic Surgical Resection in Multiple Lung Cancer. Thorac Cardiovasc Surg 2021; 69:373.</a></li><li><a class="nounderline abstract_t">Carr SR, Schuchert MJ, Pennathur A, et al. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg 2012; 143:390.</a></li><li><a class="nounderline abstract_t">Zhou H, Kang X, Dai L, et al. Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer. Thorac Cancer 2018; 9:1062.</a></li><li><a class="nounderline abstract_t">van Rens MT, de la Rivière AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117:374.</a></li><li><a class="nounderline abstract_t">Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 2018; 378:1976.</a></li><li><a class="nounderline abstract_t">Zhang C, Yin K, Liu SY, et al. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. J Immunother Cancer 2021; 9.</a></li><li><a class="nounderline abstract_t">Osorio JC, Arbour KC, Le DT, et al. Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. J Clin Oncol 2019; 37:3546.</a></li><li><a class="nounderline abstract_t">Asmar R, Sonett JR, Singh G, et al. Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience. J Thorac Oncol 2017; 12:1524.</a></li><li><a class="nounderline abstract_t">Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398:1344.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, O'Brien MER, Mauer M, et al. VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Ann Oncol 2022; 33:451.</a></li><li><a class="nounderline abstract_t">Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 2020; 383:1711.</a></li><li><a class="nounderline abstract_t">Zhang Z, Gao S, Mao Y, et al. Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers. Sci Rep 2016; 6:23252.</a></li><li><a class="nounderline abstract_t">Rea F, Zuin A, Callegaro D, et al. Surgical results for multiple primary lung cancers. Eur J Cardiothorac Surg 2001; 20:489.</a></li><li><a class="nounderline abstract_t">Hamaji M, Allen MS, Cassivi SD, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg 2013; 145:683.</a></li><li><a class="nounderline abstract_t">van Rens MT, Zanen P, Brutel de La Rivière A, et al. Survival in synchronous vs. single lung cancer: upstaging better reflects prognosis. Chest 2000; 118:952.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Finley DJ, Fabian T, et al. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol 2013; 24:889.</a></li><li><a class="nounderline abstract_t">Creach KM, Bradley JD, Mahasittiwat P, Robinson CG. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol 2012; 104:19.</a></li><li><a class="nounderline abstract_t">Chen C, Wu Z, Wu Z, et al. Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database. BMC Cancer 2021; 21:666.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf-accessed 3/21/2013. (Accessed on March 21, 2013).</li></ol></div><div id="topicVersionRevision">Topic 4637 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25873504" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathologists' staging of multiple foci of lung cancer: poor concordance in absence of dramatic histologic or molecular differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649447" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649447" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944304" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873175" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461399" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The 7th Edition of TNM in Lung Cancer: what now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23754705" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Worldwide trend of increasing primary adenocarcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16604529" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008692" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17008692" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671847" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25911330" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216592" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29625247" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Added Value of 50-Gene Panel Sequencing to Distinguish Multiple Primary Lung Cancers from Pulmonary Metastases: A Systematic Investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31103780" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471310" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28866070" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30721797" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33845213" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21926387" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8313318" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15246183" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26179249" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence for a genetical contribution to non-smoking-related lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29626620" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13094644" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26558321" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Disease Recurrence and Second Tumors in Long-term Survivors of Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747865" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Second lung cancers in patients after treatment for an initial lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23127371" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33722709" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tobacco Smoking and Risk of Second Primary Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392619" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533031" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24002495" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154811" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Resected synchronous primary malignant lung tumors: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021769" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Surgical results of synchronous multiple primary lung cancers: similar to the stage-matched solitary primary lung cancers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17873169" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409811" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : European trends in preoperative and intraoperative nodal staging: ESTS guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101145" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictors of outcomes after surgical treatment of synchronous primary lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25617985" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26525847" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pulmonary Metastases from NSCLC and MPLC (Multiple Primary Lung Cancers): Management and Outcome in a Single Centre Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22553198" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22975611" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796858" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of medically inoperable non-small-cell lung cancer with stereotactic body radiation therapy versus image-guided tumor ablation: can interventional radiology compete?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321323" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26581137" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981812" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145532" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23043577" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of stereotactic body radiation therapy for medically inoperable multiple primary lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385795" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746675" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23798353" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659504" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Stereotactic Body Radiotherapy for Synchronous Primary Lung Cancer: Clinical Outcome of 18 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25889747" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25889747" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25725930" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A meta-analysis of resected metachronous second non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443159" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcomes after Contralateral Anatomic Surgical Resection in Multiple Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22169444" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29917320" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of repeated surgery is superior to that of non-surgery for recurrent/second primary lung cancer after initial operation for primary lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669677" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29658848" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33820821" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31675272" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28647671" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34555333" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15–PEARLS/KEYNOTE-091 study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32955177" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27254665" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11509268" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Surgical results for multiple primary lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414986" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11035662" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Survival in synchronous vs. single lung cancer: upstaging better reflects prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23136230" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22248508" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Stereotactic body radiation therapy in the treatment of multiple primary lung cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34088283" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
